Aligos Therapeutics (ALGS)

• Market cap: $30.4M
• 1 day: -8.05%
• 5 days: -13.86%
• 1 month: -22.68%
• 3 months: -26.28%
• 6 months: -50.85%
• Year to date: -46.22%
• 1 year: -18.84%
• 5 years: -99.34%
• 10 years: -98.68%
• Sector: Healthcare
• Industry: Biotechnology

About: Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Employees: 82